[DS8201-A-U207] A phase 2, multicenter, randomized study of trastuzumab deruxtecan in subjects with HER2-overexpressing locally advanced, unresectable or metastatic colorectal cancer (Destiny-CRC02)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Daiichi Sankyo Inc
Start Date
April 22, 2021
End Date
May 9, 2026
Administered By
Duke Cancer Institute
Awarded By
Daiichi Sankyo Inc
Start Date
April 22, 2021
End Date
May 9, 2026